Gyre Therapeutics (GYRE) Misses Q2 EPS by 6c

Gyre Therapeutics (NASDAQ: GYRE) reported Q2 EPS of ($0.12), $0.06 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $26.49 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Is the global equity rally broadening? UBS weighs in